OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis $22.00 -0.01 (-0.02%) As of 08/9/2022 Add Compare Share Share Stock Analysis Stock Analysis About H. Lundbeck A/S Stock (OTCMKTS:HLUYY) Get H. Lundbeck A/S alerts:Sign Up Key Stats Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/AConsensus RatingN/A Company Overview H. Lundbeck A/S is a Denmark-based pharmaceutical company focused on developing, manufacturing and commercializing medicines for brain diseases. Its research and commercial activities address conditions including depression, schizophrenia, migraine, alcohol dependence and other neurological and psychiatric disorders. The company’s portfolio includes Vyepti (eptinezumab) for the preventive treatment of migraine, Trintellix (vortioxetine) for major depressive disorder, Rexulti (brexpiprazole) for selected psychiatric indications, and Abilify Maintena (aripiprazole) for the treatment of schizophrenia and maintenance treatment of bipolar I disorder. Lundbeck also markets other products and medicines through its own development programs and strategic collaborations. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and serves patients and healthcare professionals through commercial operations in numerous countries across North America, Europe and other international markets. The company’s global activities include research, clinical development, regulatory support, manufacturing and sales. H. Lundbeck A/S is led by Chief Executive Officer Charl van Zyl.AI Generated. May Contain Errors. Read More Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLUYY Stock News HeadlinesH LUNDBECK A/S AAugust 21, 2026 | finanznachrichten.deH LUNDBECK A/S BJuly 24, 2026 | finanznachrichten.deShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.September 12 at 1:00 AM | Chaikin Analytics (Ad)H. Lundbeck A/SEO-Medium-Term Nts 2025(25/29) BondJuly 7, 2026 | markets.businessinsider.comAvadel board declares Lundbeck proposal superior to Alkermes offerNovember 17, 2025 | msn.comAvadel Pharmaceuticals plc Confirms Receipt of Unsolicited Acquisition Proposal from H. Lundbeck A/SNovember 14, 2025 | quiverquant.comQLundbeck and Contera partner for oligonucleotide-based medicinesOctober 22, 2025 | msn.comH. Lundbeck A/S Cl BOctober 12, 2025 | barrons.comSee More Headlines HLUYY Stock Analysis - Frequently Asked Questions How have HLUYY shares performed this year? H. Lundbeck A/S's stock was trading at $22.00 on January 1st, 2026. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) announced its earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to analyst estimates of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%. Does H. Lundbeck A/S have any subsidiaries? The following companies are subsidiaries of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2015Today9/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:HLUYY CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Trailing Twelve Months)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:HLUYY) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy ‘one day’ retirement secretTradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...TradeSmith | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
